Literature DB >> 12423244

Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival.

Gwang Lee1, Eunsung Junn, Mikiei Tanaka, Yong Man Kim, M Maral Mouradian.   

Abstract

Parkinson's disease is characterized by loss of nigral dopaminergic neurons and the presence of cytoplasmic inclusions known as Lewy bodies. alpha-Synuclein and its interacting partner synphilin-1 are among constituent proteins in these aggregates. The presence of ubiquitin and proteasome subunits in these inclusions supports a role for this protein degradation pathway in the processing of proteins involved in this disease. To begin elucidating the kinetics of synphilin-1 in cells, we studied its degradation pathway in HEK293 cells that had been engineered to stably express FLAG-tagged synphilin-1. Pulse-chase experiments revealed that this protein is relatively stable with a half-life of about 16 h. Treatment with proteasome inhibitors resulted in attenuation of degradation and the accumulation of high molecular weight ubiquitinated synphilin-1 in immunoprecipitation/immunoblot experiments. Additionally, proteasome inhibitors stimulated the formation of peri-nuclear inclusions which were immunoreactive for synphilin-1, ubiquitin and alpha-synuclein. Cell viability studies revealed increased susceptibility of synphilin-1 over-expressing cells to proteasomal dysfunction. These observations indicate that synphilin-1 is ubiquitinated and degraded by the proteasome. Accumulation of ubiquitinated synphilin-1 due to impaired clearance results in its aggregation as peri-nuclear inclusions and in poor cell survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423244     DOI: 10.1046/j.1471-4159.2002.01136.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.

Authors:  Makoto Hashimoto; Kohichi Kawahara; Pazit Bar-On; Edward Rockenstein; Leslie Crews; Eliezer Masliah
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Synphilin-1 inhibits alpha-synuclein degradation by the proteasome.

Authors:  Beatriz Alvarez-Castelao; José G Castaño
Journal:  Cell Mol Life Sci       Date:  2010-11-20       Impact factor: 9.261

3.  The Protein Complex of Neurodegeneration-related Phosphoinositide Phosphatase Sac3 and ArPIKfyve Binds the Lewy Body-associated Synphilin-1, Preventing Its Aggregation.

Authors:  Ognian C Ikonomov; Diego Sbrissa; Lauren M Compton; Rita Kumar; Ellen J Tisdale; Xuequn Chen; Assia Shisheva
Journal:  J Biol Chem       Date:  2015-09-24       Impact factor: 5.157

4.  Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue.

Authors:  Melanie Dyllick-Brenzinger; Cheryl A D'Souza; Burkhardt Dahlmann; Peter-Michael Kloetzel; Anurag Tandon
Journal:  Neurotox Res       Date:  2009-08-04       Impact factor: 3.911

5.  Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.

Authors:  Esti Liani; Allon Eyal; Eyal Avraham; Revital Shemer; Raymonde Szargel; Daniela Berg; Antje Bornemann; Olaf Riess; Christopher A Ross; Ruth Rott; Simone Engelender
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

Review 6.  A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.

Authors:  Casey Cook; Leonard Petrucelli
Journal:  Biochim Biophys Acta       Date:  2009-02-03

7.  Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.

Authors:  V Uma Bai; Ok Hwang; George W Divine; Evelyn R Barrack; Mani Menon; G Prem-Veer Reddy; Clara Hwang
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

8.  The Guanine nucleotide exchange factor kalirin-7 is a novel synphilin-1 interacting protein and modifies synphilin-1 aggregate transport and formation.

Authors:  Yu-Chun Tsai; Olaf Riess; Anne S Soehn; Huu Phuc Nguyen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.